Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

The impact of sociodemographic factors on thyroid cancer trends in the United States: A retrospective study using SEER database.

Stanley Ntow Atencah, Samuel Dadzie, Oboseh John Ogedegbe et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18163

e18163 Background: Thyroid cancer remains a significant cause of morbidity and mortality in the US. The American Cancer Society reports approximately 44,0...

Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).

Yufan Qiu, Nazli Dizman, Yan Jiang et al. Jun 01, 2025 pp. 9511-9511 10.1200/jco.2025.43.16_suppl.9511

9511 Background: Dietary fiber intake is associated with response to ICB in melanoma. HFDIs favorably modulate the microbi...

Survival outcomes of patients with de novo stage metastatic head and neck cancer: A single center experience.

Heya Batah, Moath Albliwi, Bader Abou Shaar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18024

e18024 Background: Metastatic head and neck cancer (HNC) at the time of diagnosis is rare and occurs in 10% of cases. It has a poor prognosis, however, im...

NUT carcinoma: Survival outcomes and epidemiology.

Hassan Ali, Shammas Bajwa, Sivaguha Yadunath Prabhakaran et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22540

e22540 Background: NUT carcinoma (NC) or NUT midline carcinoma is an extremely rare, undifferentiated or a poorly differentiated squamous cell malignancy...

Comparative analysis of immunotherapy treatments in non-small cell lung cancer (NSCLC) using novel causal machine learning approaches.

Dan Goldstaub, Gal Shoham Levin, Tzviel Frostig et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20598

e20598 Background: While immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment, predicting immune-related a...

Overview of endocrine malignancies in Jordan: Insights from the MENA region.

Omar Daas, Osama Mustafa Younis, Asem Abuhamdan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22583

e22583 Background: Endocrine cancers, particularly thyroid malignancies, are increasing globally, with variations across regions. In the MENA region, ther...

Unveiling prostaglandin D2 signaling axis in the tumor microenvironment for immune modulation and prognosis in lung adenocarcinoma.

Qiang Liu, Huiguo Chen, Dongfang Tang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20057

e20057 Background: Tumor metabolism reprogramming is a hallmark of cancer, but metabolite-mediated intercellular communication remains poorly understood....

Tolerability and outcomes with serial cycles of 28 days of venetoclax in newly diagnosed patients with AML.

Jesse Sanchez, Michael Kenneth Jones, Katie Julian et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18527

e18527 Background: The standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) unable to tolerate intensive induction chemotherapy...

Revolutionizing bladder cancer follow-up: Personalized urinary ctDNA analysis for detecting minimal residual disease.

Xuebin Wan, Zikuan Zhang, Jiaman Teng et al. Jun 01, 2025 pp. 4584-4584 10.1200/jco.2025.43.16_suppl.4584

4584 Background: As one of the most common malignant neoplasms of the urinary tract, bladder cancer (BC) has received widespread attention with respect to...

EGFR missense mutations to predict skeletal metastasis in lung cancer patients.

Gowhar Shafi, Aarthi Ramesh, Bharat Bhosale et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14541

e14541 Background: EGFR is a commonly mutated gene in several cancer types, particularly lung cancer. The specific mutation can cause susceptibility or re...

ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).

Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore et al. Jun 01, 2025 pp. 5005-5005 10.1200/jco.2025.43.16_suppl.5005

5005 Background: In 2021, final prespecified OS (key secondary endpoint; defined as time from randomization to death from...

Designing a novel ProActive-CV clinic model to address cardiovascular risk in prostate cancer survivorship at a large safety-net hospital.

Viral M. Patel, Nicholas Levonyak, Phu Vincent Nguyen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23224

e23224 Background: Prostate cancer (PCa) is the most common cancer in males. As survival rates increase, management strategies must adapt to address long-...

Prognostic factors associated with distant recurrence in patients with intimal sarcoma at a tertiary sarcoma referral center in Latin America.

Javier Antonio Méndez López, Cristian Vargas, Elí Emmanuel Santana Aguilar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23565

e23565 Background: Intimal sarcoma (InS) is an extremely rare and aggressive subtype of soft tissue sarcoma, typically originating in large mediastinal ve...

Adjuvant chemotherapy outcomes among patients with stage II early-onset colon cancer in Alberta.

Robert Barkev Basmadjian, Dylan O'Sullivan, Tamer N. Jarada et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15629

e15629 Background: Incidence rates of early-onset colorectal cancer (eoCRC) among adults under the age of 50 years are increasing in Canada and the United...

Insurance disparities among subgroups of Hispanic Americans with cancer.

Isabella Nguyen, Lilac Nguyen, Emily Feng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13775

e13775 Background: Hispanic Americans, the second-largest racial/ethnic group in the U.S., make up approximately 19% of the population and experience comp...

TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.

Mazyar Shadman, Philip Thompson, Benjamin Heyman et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps7091

TPS7091 Background: Bispecific CD20 x CD3 TCEs are changing the treatment landscape for pts with r/r non-Hodgkin lymphomas (NHL); however, they are associ...

Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma.

Yu Su, Xue Cong Zhu, Jin Yang et al. Jun 01, 2025 pp. 2554-2554 10.1200/jco.2025.43.16_suppl.2554

2554 Background: Esophageal squamous cell carcinoma (ESCC) is one of the most common digestive malignant tumor with the highest mortality rate in China.Re...

Disparities and trends in gastric cancer: Incidence, mortality, and stage-specific trends.

Silpa Choday, Anthony Yeung, Varun Vankeshwaram et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16063

e16063 Background: Gastric cancer remains a significant global health burden. This study aims to provide a comprehensive analysis of gastric cancer incide...

Prognostic awareness in older adults with metastatic cancer: Secondary analysis of a randomized controlled trial.

Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Marianne Razavi et al. Jun 01, 2025 pp. 1624-1624 10.1200/jco.2025.43.16_suppl.1624

1624 Background: Prognostic awareness plays a key role in patient outcomes, particularly among older adults with metastatic cancer. This secondary analysi...

Impact of pelvic lymph node dissection on survival outcomes in non-muscle invasive bladder cancer: A multicenter retrospective study.

Shiwang Huang, Yunkai Qie, Chong Shen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16594

e16594 Background: Pelvic lymph node dissection (PLND) is a standard component of radical cystectomy (RC) in patients with muscle-invasive bladder cancer...

Prevalence of pathogenic germline variants in hereditary breast/ovarian cancer patients at the National Cancer Genetic Counseling Center in Costa Rica.

Geiner Jiménez Jiménez, Carlos Santamaría Quesada, Paula Quesada Soto et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17567

e17567 Background: There is limited information on pathogenic germline variants prevalence in Hereditary Breast/Ovarian Cancer (HBOC) across the Central A...

Mortality and readmission rates post CAR-T cell therapy in relapsed/refractory multiple myeloma: Real-world, multicentre, retrospective cohort study using TriNetX database.

Kanika Goyal, Nikhil Vojjala, Deevyashali Parekh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19564

e19564 Background: Immunotherapy, particularly CAR T-cell therapy, emerges as a promising frontier in the ongoing pursuit of effective multiple myeloma tr...

The impact of race/ethnicity on outcomes in patients with follicular lymphoma in the United States: A nationwide analysis.

Dosbai Saparov, Kibwey Peterkin, Henry Becerra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19061

e19061 Background: Evidence in Racial/Ethnic (RE) disparities in Follicular Lymphoma (FL) has been limited to certain number of RE groups, and others incl...

Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.

Elena Sevillano, Julia Martinez Perez, Nuria Lainez Milagro et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4626

TPS4626 Background: Radical cystectomy (RC), traditionally considered the gold standard for MIBC, carries significant morbidity, negatively impacting pati...

SLAMF8 as a potential therapeutic target for modulating tumor-associated macrophages in colorectal cancer.

Han Xingzhi, Xiaoping Qian, Qun Zhang Jun 01, 2025 pp. 2573-2573 10.1200/jco.2025.43.16_suppl.2573

2573 Background: Reprogramming or repolarizing tumor-associated macrophages (TAMs) has emerged as a novel strategy in tumor immunotherapy, leveraging thei...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page